SETDB1 and lung carcinoma: Moreover, new research shows that SETDB1 fuels the phenotype of lung cancer by modulating the epigenome and resists anti-CTLA4 and anti-PD1 combination therapy (Griffin et al., 2021; Zakharova et al., 2022).